Jerry Estep is the current Chairman of Cardiology, Cleveland Clinic Florida. He served as the Section Head of Heart Failure and Heart Transplantation and the Medical Director of the Kaufman Center for Heart Failure and Recovery at Cleveland Clinic in Ohio from 2018 to 2022. He holds board certification in advanced heart failure (HF) and transplant and cardiovascular disease. Over the past 15 years his primary goal has been to expand clinical, research and education efforts at two large hospital systems. Prior to joining the Cleveland Clinic he served as Medical Director of the Mechanical Circulatory Support Program and Heart Transplant program at Houston Methodist. Both the Cleveland Clinic and Houston Methodist have comprehensive heart failure programs that leverage multidisciplinary teams to enhance access and referrals with a focus on delivering high quality of care coupled with innovation in research and education.
Jerry Estep has authored/coauthored more than 150 manuscripts and/or published abstracts. In addition he has given over 100 presentations related to heart failure topics at major society meetings and/or at academic institutions. His peer reviewed manuscripts including both original reviews and investigation in several heart failure domains including the role of multimodality imaging to monitor heart failure patients and advanced heart failure topics related to mechanical circulatory support devices and heart transplantation. These manuscripts have been published in the New England Journal of Medicine, Circulation, Journal of the American College of Cardiology (JACC), JACC CV Imaging, and The Journal of Heart and Lung Transplantation (JHLT).
Jerry Estep has served as site PI/or co-PI in over 100 clinical trials. He had the privilege of serving as the lead national investigator of the Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP) Study. He was the senior author of our multisite randomized controlled trial effort focused on defining the efficacy of a patient-centered Ventricular Assist Device Decision Aid (VADDA Trial). He also had the opportunity to serve as Co-Chair for the American Society of Echocardiography (ASE) Guidelines and Statement Document that defined the role of echocardiography to monitor patients supported by left ventricular assist devices (LVADs). He is the current Chair for the ASE updated guidelines statement that defines the role of multimodality imaging to select and monitor patients supported by LVADs and temporary mechanical support devices. In addition, he was the Co-Chair for the Flow Optimization Working Group Committee for the landmark Momentum Heart Mate 3 Trial. Based on his heart failure and trial expertise, he is currently serving as one the National Co-PIs for the Clinical Study of the BioVentrix Revivent TC System for Treatment of Left Ventricular Aneurysms (ALIVE) NCT02931240. Based on these experiences, he appreciates the importance of aligning clinical infrastructure with clinical research and education. His experience overseeing large multi-disciplinary teams focused on providing the highest clinical quality coupled with nationally recognized efforts in research and education positions him to help lead cardiovascular medicine efforts at Cleveland Clinic Florida.